Lijun International Pharmaceutical (Holding) Co. Ltd.

23andMe Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, November 8, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.
  • Members of Total Health will also receive all the reports and features offered in our existing 23andMe+ Premium Membership.
  • Full year Adjusted EBITDA deficit is reaffirmed to be in the range of $180 to $160 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, November 8, 2023, to discuss the financial results for Q2 FY2024 and report on business progress.

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

Retrieved on: 
Tuesday, November 7, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.
  • Members of Total Health will also receive all the reports and features offered in the Company’s existing 23andMe+ Premium Membership .
  • As part of Total Health, members will gain access to all the premium reports and features delivered through 23andMe+ Premium.
  • The 23andMe+ Total Health membership will cost $99 per month, billed in a one-time annual payment of $1,188.

23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data

Retrieved on: 
Tuesday, October 31, 2023

Eligible customers may also receive recommendations for further clinical action, like getting a blood test, which can now be coordinated directly through 23andMe.

Key Points: 
  • Eligible customers may also receive recommendations for further clinical action, like getting a blood test, which can now be coordinated directly through 23andMe.
  • * The biomarker data, in addition to genetic data, can help identify possible health risks for individuals to take any necessary actions.
  • “Health Action Plan is a powerful tool for customers, combining genetic and non-genetic data, along with lab testing to tailor health recommendations,” said Robin Smith, Ph.D., Director of Product Management at 23andMe.
  • 23andMe reminds customers that they should not use Health Action Plan to replace a visit to their primary healthcare provider.

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Caring Across Generations to Convene Cross-Sector Leaders, Make Care Defining Issue of 2024

Retrieved on: 
Thursday, October 19, 2023

LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- On Nov. 2-3, Caring Across Generations will bring together 500 leaders across the business, entertainment, government and advocacy sectors for an in-person summit focused on the future of caregiving. The first-of-its-kind event is at the Luskin Conference Center at UCLA where cultural influencers, corporate partners, policymakers, researchers, philanthropists and care advocates will share their personal care experiences and identify opportunities to make the issue more visible in our pop culture and more accessible in our communities and workplaces.

Key Points: 
  • An art installation presented in partnership with the Center for Cultural Power and Metta Fund will showcase the cultural diversity of aging and intergenerational care in California.
  • Caring Across will also unveil three new initiatives:
    Care Inclusion Playbook is a resource for screenwriters and other content creators to develop more care-related storylines.
  • Care Catalyst Awards will recognize social media influencers who share their care stories and enable people who often feel unseen to feel less alone.
  • Caring Across Generations to convene 'CareFest' with 500 cross-sector leaders.

Global Oral Clinical Nutrition Market Predicted to Expand Significantly by 2028, Driven by Rising Chronic Diseases - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 5, 2023

The global oral clinical nutrition market is poised for substantial growth during the forecast period due to the increasing prevalence of chronic diseases and a growing emphasis on patient-centric care.

Key Points: 
  • The global oral clinical nutrition market is poised for substantial growth during the forecast period due to the increasing prevalence of chronic diseases and a growing emphasis on patient-centric care.
  • Additionally, the rise in malnutrition and related conditions like sarcopenia and cachexia is boosting the demand for oral clinical nutrition products.
  • Rising Chronic Diseases: The escalating incidence of chronic conditions such as diabetes, cardiovascular disease, and cancer is a significant driver of the global oral clinical nutrition market.
  • The comprehensive Global Oral Clinical Nutrition Market report covers market segmentation by indication, distribution channel, and region, highlighting industry trends and growth drivers.

23andMe Granted New FDA Clearance to Report Additional BRCA Variants

Retrieved on: 
Thursday, August 31, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced the Company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report*. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer. 23andMe received the first FDA authorization for a direct-to-consumer genetic test for cancer risk in 2018 to report 3 variants in the BRCA1 and BRCA2 genes, primarily found in people of Ashkenazi Jewish descent. Many of the 41 BRCA variants added through this clearance are known to have a higher rate of occurrence in populations traditionally underserved by genetic testing, including the African American and Hispanic/Latino communities. This marks the Company’s fourth FDA clearance for genetic cancer risk.

Key Points: 
  • The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer.
  • In addition to the 510(k) clearance, the FDA also granted 23andMe the first-ever Predetermined Change Control Plan (PCCP), which allows the Company to add additional validated BRCA1 and BRCA2 variants and associated cancer risk information to its BRCA1/BRCA2 (Selected Variants) report without additional premarket review.
  • 23andMe also underwent robust analytical validation in order to meet FDA requirements to add variants to the BRCA1/BRCA2 (Selected Variants) report.
  • This clearance is the eighth pre-market authorization granted by the FDA to 23andMe covering its multiplexed Personal Genome Service.

Vertiv Announces Commencement of Secondary Offering of 20,000,000 Shares of Common Stock by VPE Holdings, LLC, an affiliate of Platinum Equity, LLC

Retrieved on: 
Monday, August 7, 2023

The closing of the offering is expected to occur on or about August 9, 2023, subject to customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about August 9, 2023, subject to customary closing conditions.
  • Vertiv is not selling any shares of Class A common stock in the offering and will not receive any proceeds from the offering.
  • BofA Securities, Inc. is acting as sole underwriter for the offering.
  • Copies of these documents may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov .

23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin

Retrieved on: 
Thursday, July 20, 2023

SOUTH SAN FRANCISCO, Calif., July 20, 2023 (GLOBE NEWSWIRE) --  23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, released a new Simvastatin Medication Insight report as part of its 23andMe+ membership service that reports on a person's likelihood of experiencing side effects from this commonly prescribed statin drug.

Key Points: 
  • Simvastatin is a commonly prescribed statin drug used to lower cholesterol in the blood and reduce the risk of heart attacks, strokes, or other heart problems.
  • “But we have also known for some time that genetic differences play a major role in the effectiveness of many medicines.
  • The insight report provides clear information about whether an individual has an increased chance of experiencing side effects.
  • About 8 million people in the US were prescribed the statin simvastatin in 2020, amounting to about 36 million prescriptions, making it among the most prescribed medications in the United States.